Background
Methods
Study design and population
Clinical data and outcomes
Lung ultrasound imaging protocol and analysis
Statistical analysis
Results
Clinical characteristics
Variables | Total population (n = 280) | LUS score | p value | ||
---|---|---|---|---|---|
Low 0–1 (n = 153) | Moderate 2–12 (n = 70) | High > 12 (n = 57) | |||
Demographic data | |||||
Age, year | 55 [40 ~ 65] | 46 [34 ~ 57] | 59 [48 ~ 68] | 69 [60 ~ 76] | < 0.001 |
Male, n (%) | 141 (50.4) | 73 (47.7) | 37 (52.9) | 31 (54.4) | 0.632 |
BMI, Kg/m [2] | 23.11 ± 3.31 | 23.24 ± 3.27 | 23.29 ± 3.08 | 23.16 ± 3.27 | 0.957 |
Temperature, ℃ | 38.4 [37.8 ~ 38.9] | 38.0 [37.8 ~ 38.8] | 38.4 [37.8 ~ 38.7] | 38.6 [38.0 ~ 39.0] | 0.042 |
Respiratory rate, min−1 | 20 [19 ~ 20] | 20 [18 ~ 20] | 20 [18.5 ~ 20] | 20 [19 ~ 21] | 0.207 |
SaO2 (%) | 98 [97 ~ 99] | 99 [98 ~ 99] | 99 [98 ~ 99] | 98 [95 ~ 99] | 0.014 |
Comorbidities, n (%) | 85 (30.4) | 25 (16.3) | 21 (30.0) | 39 (68.4) | < 0.001 |
Hypertension, n (%) | 58 (20.7) | 16 (10.5) | 15 (21.4) | 27 (47.4) | < 0.001 |
Diabetes, n (%) | 27 (9.6) | 4 (2.6) | 6 (8.6) | 17 (29.8) | < 0.001 |
Chronic cardiovascular disease, n (%) | 24 (8.6) | 6 (3.9) | 0 (0.0) | 18 (31.6) | < 0.001 |
Chronic liver diseases, n (%) | 11 (3.9) | 4 (2.6) | 2 (2.9) | 5 (8.8) | 0.161 |
Malignancy, n (%) | 13 (4.6) | 2 (1.3) | 2 (2.9) | 9 (15.8) | < 0.001 |
Laboratory results | |||||
Lymphocytes % | 24.29 ± 10.88 | 29.18 ± 8.43 | 27.55 ± 8.79 | 14.60 ± 9.32 | < 0.001 |
CRP, mg/L | 6.30 [2.00 ~ 40.13] | 2.49 [0.81 ~ 8.49] | 3.40 [1.47 ~ 10.69] | 27.43 [4.18 ~ 66.41] | < 0.001 |
D-dimer, ug/L | 0.99 [0.37 ~ 3.70] | 0.27 [0.20 ~ 0.94] | 0.34 [0.25 ~ 1.20] | 1.65 [0.85 ~ 6.52] | < 0.001 |
hs-TnI, ng/L | 2.6 [1.4 ~ 2.6] | 2.2 [1.4 ~ 2.8] | 1.7 [0.9 ~ 5.3] | 18.3 [2.5 ~ 113.2] | 0.001 |
CK-MB, U/L | 0.5 [0.3 ~ 6.0] | 0.4 [0.3 ~ 0.6] | 0.4 [0.3 ~ 0.8] | 7.0 [0.4 ~ 13.5] | 0.001 |
PaO2:FiO2, mmHg | |||||
> 300 | 246 (87.9) | 153 (100.0) | 68 (97.1) | 25 (43.9) | < 0.001 |
200–300 | 22 (7.9) | 0 (0.0) | 2 (2.9) | 20 (35.1) | < 0.001 |
≤ 200 | 12 (4.3) | 0 (0.0) | 0 (0.0) | 12 (21.1) | < 0.001 |
Treatments | |||||
Antiviral therapy, n (%) | 82 (29.3) | 19 (12.4) | 28 (40.0) | 35 (61.4) | < 0.001 |
Antibiotic therapy, n (%) | 78 (27.9) | 18 (11.8) | 26 (37.1) | 34 (59.6) | < 0.001 |
Glucocorticoid therapy, n (%) | 22 (7.9) | 3 (2.0) | 3 (4.3) | 16 (28.1) | < 0.001 |
High-flow oxygen, n (%) | 47 (16.8) | 2 (1.3) | 3 (4.3) | 42 (73.7) | < 0.001 |
Invasive mechanical ventilation, n (%) | 17 (6.1) | 0 (0.0) | 0 (0.0) | 17 (29.8) | < 0.001 |
ICU admission, n (%) | 17 (6.1) | 0 (0.0) | 0 (0.0) | 17 (29.8) | < 0.001 |
Complications | |||||
Respiratory failure, n (%) | 49 (17.5) | 2 (1.3) | 3 (4.3) | 44 (77.2) | < 0.001 |
ARDS, n (%) | 37 (13.2) | 1 (0.7) | 2 (2.9) | 34 (59.6) | < 0.001 |
Sepsis, n (%) | 14 (5.0) | 0 (0.0) | 0 (0.0) | 14 (24.6) | < 0.001 |
Acute heart injury, n (%) | 40 (14.3) | 9 (5.9) | 11 (15.7) | 20 (35.1) | < 0.001 |
Acute kidney injury, n (%) | 26 (9.3) | 0 (0.0) | 6 (8.6) | 20 (35.1) | < 0.001 |
Prognosis | |||||
Discharge, n (%) | 267 (95.4) | 153 (100.0) | 70 (100.0) | 44 (77.2) | < 0.001 |
Death, n (%) | 13 (4.6) | 0 (0.0) | 0 (0.0) | 13 (22.8) | < 0.001 |
Variables | All patients (n = 280) | Non-event (n = 243) | Event (n = 37) | p value |
---|---|---|---|---|
Demographic data | ||||
Age, year | 55 [40 ~ 65] | 52 [38 ~ 61] | 71 [63 ~ 79] | < 0.001 |
Male, n (%) | 141 (50.4) | 121 (49.8) | 20 (54.1) | 0.725 |
BMI, Kg/m [2] | 23.11 ± 3.31 | 23.21 ± 3.27 | 21.31 ± 2.96 | 0.129 |
Temperature, ℃ | 38.4 [37.8 ~ 38.9] | 38.1 [37.8 ~ 38.8] | 38.6 [38.0 ~ 39.0] | 0.113 |
Respiratory rate, min−1 | 20 [19 ~ 20] | 20 [18 ~ 20] | 20 [20 ~ 23] | 0.001 |
SaO2 (%) | 98 [97 ~ 99] | 99 [98 ~ 99] | 97 [95 ~ 99] | < 0.001 |
Comorbidities, n (%) | 85 (30.4) | 55 (22.6) | 25 (67.6) | < 0.001 |
Hypertension, n (%) | 58 (20.7) | 42 (17.3) | 16 (43.2) | 0.001 |
Diabetes, n (%) | 27 (9.6) | 14 (5.8) | 13 (35.1) | < 0.001 |
Chronic cardiovascular disease, n (%) | 24 (8.6) | 11 (4.5) | 13 (35.1) | < 0.001 |
Chronic liver diseases, n (%) | 11 (3.9) | 8 (3.3) | 3 (8.1) | 0.166 |
Malignancy, n (%) | 13 (4.6) | 6 (2.5) | 7 (18.9) | < 0.001 |
Laboratory results | ||||
Lymphocytes % | 24.29 ± 10.88 | 26.92 ± 9.38 | 13.91 ± 10.24 | < 0.001 |
CRP, mg/L | 6.30 [2.00 ~ 40.13] | 5.44 [1.48 ~ 27.40] | 28.2 [4.2 ~ 85.3] | 0.002 |
D-dimer, ug/L | 0.99 [0.37 ~ 3.70] | 0.43 [0.26 ~ 1.21] | 2.60 [1.06 ~ 7.73] | < 0.001 |
hs-TnI, ng/L | 2.6 [1.4 ~ 2.6] | 1.8 [0.9 ~ 4.7] | 22.0 [8.6 ~ 197.2] | < 0.001 |
CK-MB, U/L | 0.5 [0.3 ~ 6.0] | 0.4 [0.3 ~ 0.6] | 9.0 [3.8 ~ 30.5] | < 0.001 |
PaO2:FiO2, mmHg | ||||
> 300 | 246 (87.9) | 242 (99.6) | 4 (10.8) | < 0.001 |
200–300 | 22 (7.9) | 1 (0.4) | 21 (56.8) | < 0.001 |
< 200 | 12 (4.3) | 0 (0.0) | 12 (32.4) | < 0.001 |
Treatments | ||||
Antiviral therapy, n (%) | 82 (29.3) | 58 (23.9) | 24 (64.9) | < 0.001 |
Antibiotic therapy, n (%) | 78 (27.9) | 54 (22.2) | 24 (64.9) | < 0.001 |
Glucocorticoid therapy, n (%) | 22 (7.9) | 10 (4.1) | 12 (32.4) | < 0.001 |
High-flow oxygen, n (%) | 47 (16.8) | 11 (4.5) | 36 (97.3) | < 0.001 |
Invasive mechanical ventilation, n (%) | 17 (6.1) | 0 (0.0) | 17 (45.9) | < 0.001 |
ICU admission, n (%) | 17 (6.1) | 0 (0.0) | 17 (45.9) | < 0.001 |
LUS characteristics
Variables | Total population (n = 280) | LUS score | p value | ||
---|---|---|---|---|---|
Low 0–1 (n = 153) | Moderate 2–12 (n = 70) | High > 12 (n = 57) | |||
LUS features | |||||
Pleural line, n (%) | |||||
Normal pleural line | 181 (64.6) | 152 (99.3) | 29 (41.4) | 0 (0.0) | < 0.001 |
Irregular pleural line | 99 (35.4) | 1 (0.7) | 41 (58.6) | 57 (100.0) | < 0.001 |
Blurred pleural line | 31 (11.1) | 0 (0.0) | 0 (0.0) | 31 (54.4) | < 0.001 |
B-lines, n (%) | |||||
Well-spaced B-lines < 3 | 250 (89.3) | 153 (100.0) | 70 (100.0) | 27 (47.4) | < 0.001 |
Well-spaced B-lines ≥ 3 | 176 (62.9) | 49 (32.0) | 70 (100.0) | 57 (100.0) | < 0.001 |
Multiple coalescent B-lines | 34 (12.1) | 0 (0.0) | 1 (1.4) | 33 (57.9) | < 0.001 |
Consolidation, n (%) | 46 (16.4) | 0 (0.0) | 3 (4.3) | 43 (75.4) | < 0.001 |
Pleural effusion, n (%) | 5 (1.8) | 0 (0.0) | 0 (0.0) | 5 (8.8) | < 0.001 |
Distribution of abnormal LUS features | |||||
Irregular pleural line | |||||
Anterior fields | 55 (19.6) | 1 (0.7) | 8 (11.4) | 46 (80.7) | < 0.001 |
Lateral fields | 50 (17.9) | 0 (0.0) | 5 (7.1) | 45 (78.9) | < 0.001 |
Posterior fields | 76 (27.1) | 0 (0.0) | 31 (44.3) | 45 (78.9) | < 0.001 |
No. of involved zones | 0 [0 ~ 2] | 0 [0 ~ 0] | 1 [0 ~ 2] | 6 [4 ~ 10] | < 0.001 |
Blurred pleural line | |||||
Anterior fields | 4 (1.4) | 0 (0.0) | 0 (0.0) | 4 (7.0) | 0.002 |
Lateral fields | 16 (5.7) | 0 (0.0) | 0 (0.0) | 16 (28.1) | < 0.001 |
Posterior fields | 28 (10.0) | 0 (0.0) | 0 (0.0) | 28 (49.1) | < 0.001 |
No. of involved zones | 0 [0 ~ 0] | 0 [0 ~ 0] | 0 [0 ~ 0] | 1 [0 ~ 3] | < 0.001 |
Well-spaced B-lines ≥ 3 | |||||
Anterior fields | 100 (35.7) | 14 (9.2) | 30 (42.9) | 56 (98.2) | < 0.001 |
Lateral fields | 109 (38.9) | 9 (5.9) | 44 (62.9) | 56 (98.2) | < 0.001 |
Posterior fields | 139 (49.6) | 26 (17.0) | 56 (80.0) | 57 (100.0) | < 0.001 |
No. of involved zones | 1 [0 ~ 4] | 0 [0 ~ 1] | 3 [2 ~ 4] | 9 [7 ~ 11] | < 0.001 |
Multiple coalescent B-lines | |||||
Anterior fields | 33 (11.8) | 0 (0.0) | 1 (1.4) | 32 (56.1) | < 0.001 |
Lateral fields | 32 (11.4) | 0 (0.0) | 0 (0.0) | 32 (56.1) | < 0.001 |
Posterior fields | 34 (12.1) | 0 (0.0) | 1 (1.4) | 33 (57.9) | < 0.001 |
No. of involved zones | 0 [0 ~ 0] | 0 [0 ~ 0] | 0 [0 ~ 0] | 1 [0 ~ 3] | < 0.001 |
Consolidation | |||||
Anterior fields | 17 (6.1) | 0 (0.0) | 0 (0.0) | 17 (29.8) | < 0.001 |
Lateral fields | 25 (8.9) | 0 (0.0) | 1 (1.4) | 24 (42.1) | < 0.001 |
Posterior fields | 41 (14.6) | 0 (0.0) | 2 (2.9) | 39 (68.4) | < 0.001 |
No. of involved zones | 0 [0 ~ 0] | 0 [0 ~ 0] | 0 [0 ~ 0] | 2 [1 ~ 5] | < 0.001 |
Left lung involved, n (%) | 139 (49.6) | 26 (17.0) | 56 (80.0) | 57 (100.0) | < 0.001 |
Right lung involved, n (%) | 140 (50.0) | 23 (15.0) | 60 (85.7) | 57 (100.0) | < 0.001 |
Bilateral involved, n (%) | 103 (36.8) | 0 (0.0) | 46 (65.7) | 57 (100.0) | < 0.001 |
Variables | All patients (n = 280) | Non-event (n = 243) | Event (n = 37) | p value |
---|---|---|---|---|
LUS features | ||||
Pleural line, n (%) | ||||
Normal pleural line | 181 (64.6) | 180 (74.1) | 1 (2.7) | < 0.001 |
Irregular pleural line | 99 (35.4) | 63 (25.9) | 36 (97.3) | < 0.001 |
Blurred pleural line | 31 (11.1) | 6 (2.5) | 25 (67.6) | < 0.001 |
B-lines, n (%) | ||||
Well-spaced B-lines < 3 | 250 (89.3) | 236 (97.1) | 14 (37.8) | < 0.001 |
Well-spaced B-lines ≥ 3 | 176 (62.9) | 139 (57.2) | 37 (100.0) | < 0.001 |
Multiple coalescent B-lines | 34 (12.1) | 8 (3.3) | 26 (70.3) | < 0.001 |
Consolidation, n (%) | 46 (16.4) | 22 (9.1) | 24 (64.9) | < 0.001 |
Pleural effusion, n (%) | 5 (1.8) | 3 (1.2) | 2 (5.4) | 0.131 |
Distribution of abnormal LUS features | ||||
Irregular pleural line | ||||
Anterior fields | 55 (19.6) | 25 (10.3) | 30 (81.1) | < 0.001 |
Lateral fields | 50 (17.9) | 24 (9.9) | 26 (70.3) | < 0.001 |
Posterior fields | 76 (27.1) | 49 (20.2) | 27 (73.0) | < 0.001 |
No. of involved zones | 0 [0 ~ 2] | 0 [0 ~ 1] | 7 [4 ~ 10] | < 0.001 |
Blurred pleural line | ||||
Anterior fields | 4 (1.4) | 1 (0.4) | 3 (8.1) | 0.008 |
Lateral fields | 16 (5.7) | 3 (1.2) | 13 (35.1) | < 0.001 |
Posterior fields | 28 (10.0) | 6 (2.5) | 22 (59.5) | < 0.001 |
No. of involved zones | 0 [0 ~ 0] | 0 [0 ~ 0] | 2 [0 ~ 3] | < 0.001 |
Well-spaced B-lines ≥ 3 | ||||
Anterior fields | 100 (35.7) | 63 (25.9) | 37 (100.0) | < 0.001 |
Lateral fields | 109 (38.9) | 74 (30.5) | 35 (94.6) | < 0.001 |
Posterior fields | 139 (49.6) | 103 (42.4) | 36 (97.3) | < 0.001 |
No. of involved zones | 1 [0 ~ 4] | 1 [0 ~ 2] | 10 [6 ~ 10] | < 0.001 |
Multiple coalescent B-lines | ||||
Anterior fields | 33 (11.8) | 7 (2.9) | 26 (70.3) | < 0.001 |
Lateral fields | 32 (11.4) | 7 (2.9) | 25 (67.6) | < 0.001 |
Posterior fields | 34 (12.1) | 8 (3.3) | 26 (70.3) | < 0.001 |
No. of involved zones | 0 [0 ~ 0] | 0 [0 ~ 0] | 2 [0 ~ 3] | < 0.001 |
Consolidation | ||||
Anterior fields | 17 (6.1) | 5 (2.1) | 12 (32.4) | < 0.001 |
Lateral fields | 25 (8.9) | 10 (4.1) | 15 (40.5) | < 0.001 |
Posterior fields | 41 (14.6) | 19 (7.8) | 22 (59.5) | < 0.001 |
No. of involved zones | 0 [0 ~ 0] | 0 [0 ~ 0] | 2 [0 ~ 5] | < 0.001 |
Left lung involved, n (%) | 139 (49.6) | 103 (42.4) | 36 (97.3) | < 0.001 |
Right lung involved, n (%) | 140 (50.0) | 103 (42.4) | 37 (100.0) | < 0.001 |
Bilateral involved, n (%) | 103 (36.8) | 67 (27.6) | 36 (97.3) | < 0.001 |
LUS score | 1 [0 ~ 6] | 1 [0 ~ 3] | 32 [21 ~ 49] | < 0.001 |
Determination of discrimination abilities of independent predictors of adverse outcomes
Predictors of adverse outcomes in patients with COVID-19
Variables | Univariate Cox regression | Model 1 Age + Lymphocytes% + Comorbidity | Model 2 Age + Lymphocytes% + Comorbidity + LUS score | Model 3 Age + Lymphocytes% + Comorbidity + LUS score > 12 | ||||
---|---|---|---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
Age, years | 1.081 (1.057, 1.106) | < 0.001 | 1.040 (1.011, 1.070) | 0.007 | 1.032 (1.001, 1.063) | 0.041 | 1.028 (0.999, 1.059) | 0.06 |
Male (yes vs. no) | 1.074 (0.558, 2.068) | 0.83 | ||||||
BMI, Kg/m [2] | 0.828 (0.622, 1.103) | 0.197 | ||||||
Lymphocytes% | 0.872 (0.836, 0.909) | < 0.001 | 0.892 (0.853, 0.932) | < 0.001 | 0.937 (0.892, 0.985) | 0.01 | 0.940 (0.897, 0.985) | 0.01 |
CRP, mg/L | 1.007 (1.002, 1.012) | 0.01 | ||||||
hs-TnI, ng/L | 1.000 (1.000, 1.001) | 0.004 | ||||||
CK-MB, U/L | 1.004 (1.001, 1.008) | 0.022 | ||||||
Comorbidity (yes vs. no) | 4.928 (2.417, 10.050) | < 0.001 | 0.994 (0.453, 2.182) | 0.987 | 0.545 (0.228, 1.299) | 0.171 | 0.695 (0.316, 1.528) | 0.366 |
LUS score | 1.083 (1.065, 1.100) | < 0.001 | 1.049 (1.023, 1.076) | < 0.001 | ||||
LUS score > 12 (yes vs. no) | 49.935 (15.296, 163.016) | < 0.001 | 10.760 (2.753, 42.049) | 0.001 | ||||
AIC | 286 | 272 | 272 | |||||
C-index | 0.866 | 0.903 | 0.902 |